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Limiting the scope of our work, we did not use full length tumstatin in comparison to 
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In conclusion, we characterized a 17 aa fragment (CP17) of the non‐collagenous domain 
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ID Predicted class Confidence 
CP17 Antioxidant protein 0.945 
SP17 Antioxidant protein 0.935 
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Supplement Figure 1: Effects of CP17 on ROS kinetics, degranulation, secretion and 
NETosis. A) Production rate after CP17 exposure shows repressed kinetics. Representative 
line-graphs of ROS production with and without CP17 and SP17 treatment. Relative light 
units (RLU) are plotted vs. time in seconds. Logarithmic x-axis for improved display of ROS 
production ramp-up phase. B) Schematic drawing of ROS production: Treatment with SP17 
results in an unaltered rate of production (red curve) of ROS over time. At the half-maximal 
level of ROS production, the rate of ROS production (slope m) is determined. Green curve 
shows ROS production with CP17 treatment. Both areas (red, green) under the curve are 
equal and an end-point measurement of accumulated ROS would detect no difference. C) 
IL-8 secretion after R848 stimulation is not altered with CP17 or SP17 preincubation. D) 
Degranulation (neutrophil elastase) is not significantly altered after CP17 or SP17 treatment 
after R848 stimulation. E) NETosis is not altered with CP17 or SP17 treatment. Neutrophils 
were stimulated with 10nM PMA and fluorescent signal of secreted DNA was measured after 
2h and referenced to standard curve. Plot displays number of NETs vs. peptide 
concentration. Dashed line CP17, straight line SP17, x-axis at logarithmic scale. 
Supplement Figure 2: CP17 has no effect on lung function and chemokine production 
in exacerbating animals. Animals were prepared as described in the methods sections. A) 
Comparison of lung resistance at 100mg/mL methacholine in animals, which received PBS, 
SP17, CP17 only, OVA alone or with respective peptides and polyI:C together SP17 or 
CP17. Significant increases in airway resistance were observed OVA vs. PBS and PolyI:C 
vs. OVA. ****p<0.0001 B) Comparison of lung compliance at 100mg/mL methacholine in 
animals, which received PBS, SP17, CP17 only, OVA alone or with respective peptides and 
polyI:C together SP17 or CP17. *p<0.05, ****p<0.0001, n.s. = not significant C) Neither 
CP17 nor SP17 shows an impact on total lung mRNA expression of CXCL1 (KC). n.s. = not 
significant D) CCL20 mRNA expression in total lung homogenates is not significantly altered 
after CP17 treatment. *p<0.05, n.s. = not significant E) CP17 reduces bronchoalveolar 
lavage neutrophil cell counts in a mouse model of neutrophil asthma when compared to 
SP17. # p<0.05 OVA+LPS vs. PBS, ## p<0.01 OVA+LPS vs. PBS, * p<0.05 CP17 vs. SP17 
in OVA+LPS F) Macrophages and lymphocytes are increased in bronchoalveolar lavage 
after OVA and LPS challenge (neutrophilic asthma mouse model) but remain unchanged 
after peptide treatment. No effects observed for eosinophil granulocytes in BAL. **p<0.01, 
PBS vs. OVA+LPS G) Assessment of mucus producing cells in OVA only groups using a 
newCAST system. Number of mucus producing cells are not altered with CP17 treatment. H) 
Mucus producing cells (MPC) are significantly reduced after CP17 (vs. SP17) treatment in 
animals with OVA+LPS challenge. PBS vs. OVA+LPS CP17 n.s. = not significant, PBS vs. 
OVA+LPS SP17 ### p<0.001, **p<0.01 
Other Supporting Information 
The R code for the migration analysis is publicly available here: 
https://github.com/cells2numbers/2017_migration_analysis_tumstatin 
Supplement Methods: 
SiMA Tracking quality measures 
To further assess the quality of the tracking results we followed the scheme presented in [27] 
and calculated the valid observation time (VOT) which is defined as the length of all valid 
trajectories divided by the sum of the length of all valid and invalid trajectories. The VOTs for 
all analysed experiments are summarised in Suppl. Table ST1 and reveal a high tracking 
quality with an average VOT of 0.84. 
NETosis Screening Assay 
Assay was performed as previously described [59], Briefly, neutrophil concentration was set 
to 1x106/mL in medium (0.5% BSA in RPMI) including a standard curve in 5-plets. Final 
number of cells were (multiplied by 103) 75, 50, 25, 12.5, 6.25 neutrophils per well (steril 96- 
well plate, clear bottom, black rims, Corning, Simga-Aldrich, Germany). For stimulation, each 
well contained 35.000 neutrophils in 100μL 0.5% BSA/RPMI1640 (Biochrom AG, Berlin, 
Germany) and 10nM PMA (in DMSO vehicle) was used for stimulation. Neutrophils were 
pre-incubated with SP17 or CP17 at 0.5, 5.0 and 50.0 μM for 1h at 37ÅãC, 5%CO2 before 
10nM PMA was added and final incubation for 2.5h. The 96-well plate was then centrifuged 
for 5min at 500rcf, 2μg/mL propidium-iodide was added to each well (incubated for 15min) 
and plate was measured (ex544nm, em590nm) with spectrometer (FLUOStar Omega, BMG, 
Germany). From the standard curve the fluorescence signal was used to calculate NETs 
numbers. All measurements were performed as replicates of 5. 
Stimulation for secretion and degranulation 
Neutrophil concentration adjusted to 1x106/mL in medium (0.5% BSA in RPMI). Cells were 
preincubated with SP17 or CP17 at 0.5, 5.0 and 50.0 μM for 1h at 37ÅãC, 5%CO2 and 
subsequently stimulated (vehicle control for peptides, H20) with 1.5 μg/mL R848 (Invivogen). 
Cells were incubated at 37ÅãC with 5%CO2 for 1 h NE and MMP‐9 measurements, or 24 h for 
CXCL8 measurements. Cell‐free supernatant and neutrophil cell pellets were collected and 
stored at −80ÅãC for analysis. 
IL-8 enzyme-linked immunosorbent assay (ELISA) 
CXCL8 production was measured using a sandwich ELISA in duplicate. Specific ELISA kits 
from R&D Systems (Minneapolis, MN, USA) were used according to the manufacturer's 
instructions. Detection limit was 15.6 pg/mL. The plate was then measured with a 
spectrometer (FLUOStar Omega, BMG, Germany). 
NE activity assay 
NE activity was measured in triplicates using a fluorescent assay from Cayman Chemicals 
(Ann Arbor, MI, USA) according to the manufacturer's instructions. Fluorescence readings 
from samples were compared with a standard curve of known concentrations of NE to 
determine the concentration. Detection limit was 3.1 ng/mL. 
Mouse Model with LPS-OVA 
Exacerbation model was established as previously described [30]. Briefly, mice were 
sensitized to OVA/LPS by inhalation (OVA grade VI, Sigma, Deisenhofen, Germany) on 
days 1 and 7. Mice were exposed three times to an OVA (OVA grade V, Sigma) aerosol (1% 
wt/vol in PBS) on days 14 and15 in order to induce acute allergic airway inflammation. An 
amount of 1nmole CP17, vehicle (PBS) or scrambled peptide (SP17) was co-instilled after 
the OVA exposure and on day 14 and 15. All animals were sacrificed by cervical dislocation 
under deep anesthesia on day 16. Control animals were sham sensitized to PBS, received 
treatment and were subsequently challenged with PBS aerosol (PBS group). Bronchoalveolar 
lavage, lung tissue samples and serum were collected. 
